Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632708 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
A Phase 1 study of Untreated AML and Newly Diagnosed Acute Myeloid Leukemia (AML), sponsored by Institut de Recherches Internationales Servier.
- Active
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 17
- Study locations
NCT02632708 is a Phase 1 study of Untreated AML and Newly Diagnosed Acute Myeloid Leukemia (AML) that is active but no longer recruiting, run by Institut de Recherches Internationales Servier. The registered enrollment target is 153 participants. The trial reports 17 study locations across 12 states.
The verdict
NCT02632708, a Phase 1 study of Untreated AML and Newly Diagnosed Acute Myeloid Leukemia (AML), is active but no longer recruiting, sponsored by Institut de Recherches Internationales Servier.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study plans to evaluate up to 2 dose levels of AG-120 in participants with an isocitrate dehydrogenase protein 1 (IDH1) mutation and up to 2 dose levels of AG-221 in participants with an isocitrate dehydrogenase protein 2 (IDH2) mutation. AG-120 or AG-221 will be administered with 2 types of AML induction therapies (cytarabine with either daunorubicin or idarubicin) and 2 types of AML consolidation therapies (mitoxantrone with etoposide \[ME\] or cytarabine). After consolidation therapy, participants may continue on to maintenance therapy and receive daily treatment with single-agent AG-120 or AG-221 until relapse, development of an unacceptable toxicity, or hematopoietic stem cell transplant (HSCT). The study will end when all participants have discontinued study treatment.
Conditions Studied
Interventions
- DRUG AG-120
- DRUG AG-221
- DRUG cytarabine
- DRUG daunorubicin
- DRUG idarubicin
Study Locations (17)
Other
- Universitatsklinikum Ulm - Ulm
- VU Medisch Centrum - Amsterdam
- Erasmus MC - Rotterdam
California
- City of Hope - Duarte
- UCLA Medical Center - Los Angeles
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Texas
- University of Texas Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Colorado
- University of Colorado - Aurora
Illinois
- University of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2015-12-31 |
| Est. Completion | 2026-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02632708
The ClinicalTrials.gov registry entry for NCT02632708 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Untreated AML appearing as the primary indexed condition, and to 5 interventions - of which AG-120 is the first listed.
NCT02632708 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02632708 about?
NCT02632708 is a clinical study titled "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation". The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study plans to evaluate up to 2 dose levels of AG-120 in participants with an isocitrate dehydrogenase protein ...
What is the current status of trial NCT02632708?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2015-12-31. Estimated completion is 2026-07-24.
What conditions does trial NCT02632708 study?
This clinical trial studies the following conditions: Untreated AML, Newly Diagnosed Acute Myeloid Leukemia (AML), AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury.
What interventions are being tested in trial NCT02632708?
The interventions under investigation include: AG-120 (DRUG), AG-221 (DRUG), cytarabine (DRUG), daunorubicin (DRUG), idarubicin (DRUG).
Who is sponsoring clinical trial NCT02632708?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02632708 being conducted?
This trial has 17 study locations across California, Colorado, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Untreated AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RECRUITING · Phase 1
-
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Untreated AML
All registered trials for this condition
Newly Diagnosed Acute Myeloid Leukemia (AML)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.